What Has The Market Missed In Intuitive Surgical Stock’s Drop?
For questions about this article or underlying research, email help@trefis.com.
At Intuitive Surgical (ISRG), customers are trading up to the company’s newest surgical robot, the da Vinci 5, and that may be what buyers of the stock are counting on. You probably think of the company as one that grows only as fast as robotic operations do, but its sales grew faster in the third quarter of 2026. Yet the stock lost 22% over the past twelve months, while the S&P 500 returned 12.8%. That is the contradiction. So how far has da Vinci 5 pushed Intuitive Surgical’s sales?
Intuitive Surgical’s Systems Revenue Rose 30% In Q3 2026
Customers continue to trade up. Worldwide da Vinci system placements rose 28% in the third quarter of 2026, and the da Vinci 5 and the single-port SP system accounted for 65% of them. In the U.S., the company placed 335 systems, up from 263 a year earlier, as more customers converting to the da Vinci 5 signed deals for several robots at once. With that, revenue from systems grew 30% to $769 million.
The newer robots matter for the rest of the business, too. Management said revenue grew 22% in the quarter while procedures grew 15%, tying the gap to more system placements and a richer product mix as the da Vinci 5, SP and Ion become a larger part of sales.
The upgrade has not lifted the average robot price, though. A purchased da Vinci system sold for about $1.6 million on average, flat on a year earlier, because a higher mix of XiR systems offset a higher mix of da Vinci 5, management said.
Can Intuitive Surgical Outrun Its Own Instrument Price Cuts?
That has not been tested yet, because the price cuts have not taken full effect. Instrument and accessory sales reached $1.8 billion in the third quarter, so what Intuitive Surgical earns on each operation matters more than what it earns on each robot. Instrument and accessory revenue per da Vinci procedure rose to about $1,860 from $1,800 a year earlier, mainly on SP procedures and instruments made for da Vinci 5.
The shares slid after the company disclosed a $450 million litigation settlement on October 20 and narrowed its 2026 procedure growth forecast. The new range of 14% to 15% sits inside the old one of 13.5% to 15.5%, with the same midpoint. On the same call, management said new instrument pricing will cut da Vinci instrument and accessory revenue per procedure by about 3% to 5% once fully in place, a deliberate choice to win more high-volume benign procedures.
Management said that estimate leaves out the shift toward the da Vinci 5 and SP, which it expects to add to revenue per procedure. The catch is the timing. A significant cut to instrument prices in China begins in November, while the full effect of the wider cuts is not expected until the end of 2027, so the rise in revenue per procedure came before any of them.
Where Could Intuitive Surgical’s Da Vinci 5 Gains Stall?
Company-wide procedure growth hides a slower U.S. In the third quarter, da Vinci procedures grew 10% in the U.S. and 20% outside it, and management said it is watching the effects of lower ACA enrollment and changes to Medicaid eligibility. Da Vinci procedures grew 14% overall, and the 15% total also counts Ion procedures, which grew 31%. The U.S. is also where customers converting to da Vinci 5 lifted placements.
If those conversions slow, fewer robot sales would likely leave revenue growing closer to the pace of procedure growth, just as the instrument price cuts arrive. The U.S. cuts depend on a 510(k) clearance for extended use instruments, which remains in process, and management expects them to roll out beginning in the first half of 2027.
Customers are still trading up to the da Vinci 5. The newer robots have yet to show they can outweigh the instrument price cuts, and da Vinci instrument and accessory revenue per procedure is the number to watch when Intuitive Surgical reports in January 2027.
Not Sure Intuitive Surgical Is Worth It At This Price?
You don’t have to bet on one stock to earn. The Trefis Income Solution owns 50 companies chosen to keep paying dividends, each with at least 10 straight years of dividends, yielding about 3x the S&P 500.
Spot an error or want more like this? Tell us in 10 seconds.